Clinical Trials Browser

Yttrium-90 × Gastrointestinal × 90 days × Clear all

NCT05620771 2026-05-26

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma